In contrast to T cell-directed checkpoint therapies, myeloid-directed therapies can promote development of anti-tumor myeloid-derived APC, which when activated can downregulate immune checkpoint signals while promoting signaling to re-activate anergic anti-tumor T cells found in the portal blood to directly attack PDAC CTC. Here, APC is linked to neoplasm.